PMID- 30734066
OWN - NLM
STAT- MEDLINE
DCOM- 20200106
LR  - 20211002
IS  - 1433-2965 (Electronic)
IS  - 0937-941X (Linking)
VI  - 30
IP  - 6
DP  - 2019 Jun
TI  - The efficacy and safety of menatetrenone in the management of osteoporosis: a 
      systematic review and meta-analysis of randomized controlled trials.
PG  - 1175-1186
LID - 10.1007/s00198-019-04853-7 [doi]
AB  - In our systematic review and meta-analysis, we comprehensively evaluated 
      menatetrenone in the management of osteoporosis. We found that menatetrenone 
      decreased the ratio of undercarboxylated osteocalcin to osteocalcin (ucOC/OC) and 
      improved lumbar BMD compared with placebo based on the 18 studies assessed. 
      However, its benefit in fracture risk control was uncertain. INTRODUCTION: We 
      performed a systematic review and meta-analysis of the efficacy and safety of 
      menatetrenone in managing osteoporosis. METHODS: PubMed, Cochrane Library, 
      Embase, ClinicalTrials.gov , and three Chinese literature databases (CNKI, CBM, 
      Wanfang) were searched for relevant randomized controlled trials (RCTs) published 
      before October 5, 2017, comparing menatetrenone with other anti-osteoporotic 
      drugs or placebo in treating osteoporosis. The pooled risk ratio (RR) or mean 
      difference (MD) and 95% confidence interval (CI) were calculated using 
      fixed-effects or random-effects meta-analysis. RESULTS: Eighteen RCTs (8882 
      patients) were included. Pooled analyses showed that menatetrenone was more 
      effective than placebo in improving lumbar bone mineral density (BMD) (five 
      studies, N = 658, MD = 0.05 g/cm(2), 95% CI 0.01 to 0.09 g/cm(2)) and decreasing 
      ucOC/OC (two studies, N = 75, MD = - 21.78%, 95% CI - 33.68 to - 9.87%). Compared 
      with placebo, menatetrenone was associated with a nonsignificantly decreased risk 
      of vertebral fracture (five studies, N = 5508, RR = 0.87, 95% CI 0.64 to 1.20). 
      Evidence on other anti-osteoporotic drugs as comparators was limited and revealed 
      no significantly different effects of menatetrenone on BMD or fracture risks. 
      Furthermore, compared with placebo, menatetrenone significantly increased the 
      incidence of adverse events (AEs) (two studies, N = 1949, RR = 1.47, 95% CI 1.07 
      to 2.02) and adverse drug reactions (four studies, N = 6102, RR = 1.29, 95% CI 
      1.07 to 1.56). However, no significant difference in the incidence of serious AEs 
      was found between menatetrenone and placebo. CONCLUSIONS: Menatetrenone 
      significantly decreases ucOC and might improve lumbar BMD in osteoporotic 
      patients. However, its benefit in fracture risk control is uncertain.
FAU - Su, S
AU  - Su S
AD  - Department of Pharmacy, Peking University Third Hospital, 49 Huayuan North Road, 
      Haidian District, Beijing, 100191, China.
AD  - Department of Pharmacy Administration and Clinical Pharmacy, School of 
      Pharmaceutical Science, Peking University, Beijing, China.
FAU - He, N
AU  - He N
AD  - Department of Pharmacy, Peking University Third Hospital, 49 Huayuan North Road, 
      Haidian District, Beijing, 100191, China.
AD  - Department of Pharmacy Administration and Clinical Pharmacy, School of 
      Pharmaceutical Science, Peking University, Beijing, China.
FAU - Men, P
AU  - Men P
AD  - Department of Pharmacy, Peking University Third Hospital, 49 Huayuan North Road, 
      Haidian District, Beijing, 100191, China.
FAU - Song, C
AU  - Song C
AD  - Department of Orthopaedics, Peking University Third Hospital, Beijing, China.
FAU - Zhai, S
AU  - Zhai S
AD  - Department of Pharmacy, Peking University Third Hospital, 49 Huayuan North Road, 
      Haidian District, Beijing, 100191, China. zhaisuodi@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190207
PL  - England
TA  - Osteoporos Int
JT  - Osteoporosis international : a journal established as result of cooperation 
      between the European Foundation for Osteoporosis and the National Osteoporosis 
      Foundation of the USA
JID - 9100105
RN  - 0 (Bone Density Conservation Agents)
RN  - 11032-49-8 (Vitamin K 2)
RN  - 27Y876D139 (menatetrenone)
SB  - IM
EIN - Osteoporos Int. 2021 Oct;32(10):2141-2142. PMID: 34448884
MH  - Bone Density/drug effects
MH  - Bone Density Conservation Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - Lumbar Vertebrae/physiopathology
MH  - Osteoporosis/*drug therapy/physiopathology
MH  - Osteoporosis, Postmenopausal/drug therapy/physiopathology
MH  - Osteoporotic Fractures/prevention & control
MH  - Publication Bias
MH  - Randomized Controlled Trials as Topic
MH  - Sensitivity and Specificity
MH  - Treatment Outcome
MH  - Vitamin K 2/adverse effects/*analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - Efficacy
OT  - Menatetrenone
OT  - Meta-analysis
OT  - Osteoporosis
OT  - Safety
EDAT- 2019/02/09 06:00
MHDA- 2020/01/07 06:00
CRDT- 2019/02/09 06:00
PHST- 2018/07/02 00:00 [received]
PHST- 2019/01/13 00:00 [accepted]
PHST- 2019/02/09 06:00 [pubmed]
PHST- 2020/01/07 06:00 [medline]
PHST- 2019/02/09 06:00 [entrez]
AID - 10.1007/s00198-019-04853-7 [pii]
AID - 10.1007/s00198-019-04853-7 [doi]
PST - ppublish
SO  - Osteoporos Int. 2019 Jun;30(6):1175-1186. doi: 10.1007/s00198-019-04853-7. Epub 
      2019 Feb 7.